Outcomes of patients treated with teclistamab based on CMV DNAemia. (A) Response rates in patients with (n = 12) and without (n = 11) CMV DNAemia. (B) Duration of response to teclistamab in patients with and without CMV DNAemia. Log-rank, P = .2677. (C) Overall survival from the first day of teclistamab in patients with and without CMV DNAemia. Log-rank, P = .0461. CR, complete response; MR, minimal response; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.